Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials
Objective: To compare the tolerability of deutetrabenazine (DTB) and tetrabenazine (TBZ) as observed in the FIRST-HD (NCT01795859) and TETRA-HD (NCT00219804) trials for the treatment of…Temporal course of the UHDRS chorea score in Huntington disease
Objective: To describe the temporal course of Huntington disease (HD) chorea using the total maximal chorea score of the Unified Huntington Disease Rating Scale -…Temporal course of the total motor score in Huntington disease
Objective: To describe the temporal course of motor features in Huntington disease (HD) using the Unified Huntington Disease Rating Scale - Total Motor Score (UHDRS-TMS)…Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD
Objective: To assess the effect of deutetrabenazine treatment on balance using the BBT in patients with HD in First-HD. Background: Patients with HD have disrupted…Enroll-HD: A global clinical research platform for Huntington’s disease
Objective: To provide an update on the global observational registry study of Huntington's disease (HD) included in Enroll-HD, a platform for HD clinical research. Background:…Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease
Objective: To assess epidemiology and economic burden of falls and fractures among Huntington's disease (HD) patients. Background: The clinical course of HD is characterized by…Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort
Objective: To evaluate the sustained safety and efficacy following overnight switch from tetrabenazine (TBZ) to deutetrabenazine in patients with chorea associated with Huntington disease (HD).…Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD
Objective: To assess if deutetrabenazine treatment of chorea associated with HD resulted in changes in QoL, Patient Global Impression of Change (PGIC), or Clinical Global…Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study
Objective: The Swallowing Disturbance Questionnaire (SDQ) was administered to patients with Huntington disease (HD) as part of a randomized, controlled study of deutetrabenazine for the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.